🔗 Permalink

Inventor profile of:

Jack A. ROTH

City:

Houston, Texas

Country:

United States

Published Applications:

Last publication date:

2026-01-29

Top Assignees for applications by Jack A. ROTH

The entities that hold a legal rights for patent applications filed by inventor ROTH Jack A.:

Board of Regents, The University of Texas System 13 Austin, TX United States
The Board of Regents of the University of Texas System 2 Austin, TX United States
Introgen Research Institute, Inc. 1 Austin, TX United States
INTROGEN THERAPEUTICS, INC. 1 Austin, TX United States
The Board of Regents of the University of the Texas System 1 Austin, TX United States

Recent patent applications by ROTH Jack A.

Jack A. ROTH from Houston, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-01-29

US20260027180A1

Human necessities

METHODS AND COMPOSITIONS FOR TUSC2 IMMUNOTHERAPY

#2 | 2022-06-02

US20220168388A1

Human necessities

METHODS AND COMPOSITIONS FOR TUSC2 IMMUNOTHERAPY

#3 | 2020-06-25

US20200197306A1

Human necessities

CATIONIC LIQUID CRYSTALLINE NANOPARTICLES

#4 | 2020-02-06

US20200038480A1

Human necessities

Methods and compositions for TUSC2 immunotherapy

#5 | 2019-05-21

US9575473

Human necessities

Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases

#6 | 2013-10-10

US20130266634A1

Human necessities

Bioactive FUS1 peptides and nanoparticle-polypeptide complexes

#7 | 2012-09-27

US20120244209A1

Human necessities

TUSC2 THERAPIES

#8 | 2008-09-09

US10043877

Antihelminthic drugs as a treatment for hyperproliferative diseases

#9 | 2007-08-16

US20070190040A1

Chemistry; metallurgy

Recombinant p53 adenovirus methods and compositions

#10 | 2007-04-26

US20070092968A1

Human necessities

hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes

#11 | 2007-01-16

US9080935

p16 expression constructs and their application in cancer therapy

#12 | 2006-11-09

US20060251726A1

Human necessities

Bioactive FUS1 peptides and nanoparticle-polypeptide complexes

#13 | 2006-08-17

US20060182718A1

Chemistry; metallurgy

Methods and compositions comprising DNA damaging agents and p53

#14 | 2006-04-25

US10170240

Recombinant P53 adenovirus methods and compositions

#15 | 2006-03-09

US20060052322A1

Chemistry; metallurgy

Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent

#16 | 2006-02-14

US8460049

Cancer treatment with retroviral vectors comprising wild-type p53

#17 | 2006-01-05

US20060002895A1

Chemistry; metallurgy

Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery

#18 | 2005-06-30

US20050143336A1

Human necessities

Methods and compositions for improved non-viral gene therapy

#19 | 2005-06-14

US8626678

Recombinant p53 adenovirus methods and compositions

#20 | 2005-05-31

US9266465

Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery

#21 | 2005-04-28

US20050089511A1

Chemistry; metallurgy

Methods and compositions comprising DNA damaging agents and p53

#22 | 2005-02-03

US20050026139A1

Chemistry; metallurgy

Diminishing viral gene expression by promoter replacement

InventorID:

476809 ⎘